5,334 Shares in United Therapeutics Corporation $UTHR Purchased by Formula Growth Ltd.

Formula Growth Ltd. purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 5,334 shares of the biotechnology company’s stock, valued at approximately $2,890,000.

Several other hedge funds have also bought and sold shares of the stock. Callan Family Office LLC purchased a new position in United Therapeutics in the second quarter valued at $1,217,000. Leuthold Group LLC raised its position in shares of United Therapeutics by 41.4% in the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after acquiring an additional 3,126 shares during the period. UBS Group AG boosted its stake in shares of United Therapeutics by 45.3% during the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after acquiring an additional 70,445 shares in the last quarter. Nicholas Investment Partners LP boosted its stake in shares of United Therapeutics by 478.5% during the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock worth $2,218,000 after acquiring an additional 3,766 shares in the last quarter. Finally, M&T Bank Corp grew its position in shares of United Therapeutics by 171.6% during the 4th quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock valued at $1,531,000 after acquiring an additional 1,985 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at $10,311,581.28. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $541.39, for a total value of $5,143,205.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $21,933,333.07. This represents a 19.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 424,075 shares of company stock valued at $227,336,485 in the last three months. Insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of several recent analyst reports. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Royal Bank Of Canada lowered their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. JPMorgan Chase & Co. boosted their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Finally, Morgan Stanley set a $515.00 target price on United Therapeutics in a research note on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $646.00.

United Therapeutics Stock Up 2.2%

UTHR stock opened at $527.91 on Friday. United Therapeutics Corporation has a 52 week low of $302.19 and a 52 week high of $609.35. The firm has a 50-day simple moving average of $530.89 and a 200-day simple moving average of $538.86. The stock has a market capitalization of $22.64 billion, a P/E ratio of 18.89, a P/E/G ratio of 1.75 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the company posted $6.41 EPS. United Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, analysts expect that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.